SINT at a glance
The past year
Chart−57.5% $1.34, close Nov 16
- From the highest close
- −68.5%
- Vs the 200-day average
- −36.9%
Short interest
History128,437 shares
- Of shares outstanding
- 1.70%
- Since the last report
- −5.9%
- Days to cover
- 7.3 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 10 – Nov 16
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
SINT price history
Loading recent earnings…
Investment thesis
What must happen next
OEM qualification of SINT’s silicon nitride platform must convert niche technical interest into repeat commercial orders rather than one-off development work.WeakeningMateriality: High
SINT reported GAAP annual revenue in each year from FY2022 through FY2025, showing some level of commercial activity. If customers qualify the material, revenue can scale from a tiny base; if they do not, the company remains dependent on external financing.
Watch: Medical device OEMs such as Medtronic, Stryker, or Zimmer Biomet continue standardizing on titanium, PEEK, alumina, or zirconia rather than qualifying silicon nitride.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
SINT reported GAAP annual revenue in each year from FY2022 through FY2025, showing some level of commercial activity.
Open source ↗SINT’s materials must remain differentiated enough to earn high-value specialty-ceramics economics, not commodity contract-manufacturing economics.HoldingMateriality: High
FY2025 GAAP annual gross_profit was positive at $461,000 despite the small revenue base. Gross margin determines whether commercialization can fund the platform or merely adds low-quality volume.
Watch: Incumbent ceramic suppliers match the required specifications and force SINT to compete mainly on price.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual gross_profit was positive at $461,000 despite the small revenue base.
Open source ↗The operating platform has to be leveraged by commercial volume or structurally reduced; otherwise SINT’s development and manufacturing capabilities consume more cash than they can generate.WeakeningMateriality: Medium
FY2025 GAAP annual operating_income improved to a loss of $10.721 million from a loss of $14.047 million in FY2024. Operating leverage is the difference between a scalable materials platform and a perpetual loss-making lab.
Watch: Commercialization requires higher sales, quality-system, regulatory, or manufacturing spending before revenue scales.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual operating_income improved to a loss of $10.721 million from a loss of $14.047 million in FY2024.
Open source ↗SINT needs strategic funding, non-dilutive capital, or a rapid commercial inflection before cash burn forces financing on terms that dilute existing owners’ upside.WeakeningMateriality: Medium
Cash was $4.140 million at December 31, 2025, up from $3.598 million at December 31, 2024. Even if the technology eventually works, the stock may not work if shareholders are diluted before adoption arrives.
Watch: Capital markets become unavailable or punitive for small, loss-making Nasdaq medical-technology issuers.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $4.140 million at December 31, 2025, up from $3.598 million at December 31, 2024.
Open source ↗A 32-person company must win through focused partnerships and a narrow set of high-probability applications, not by trying to commercialize every possible silicon nitride use case internally.HoldingMateriality: Medium
SINT had 32 employees as of December 31, 2025. Focus can conserve cash and raise the odds of a fundable win; dispersion increases the risk that no application reaches scale in time.
Watch: Loss of key technical, manufacturing, regulatory, or business-development personnel slows customer qualification.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
SINT had 32 employees as of December 31, 2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
OEM qualification of SINT’s silicon nitride platform must convert niche technical interest into repeat commercial orders rather than one-off development work. If customers qualify the material, revenue can scale from a tiny base; if they do not, the company remains dependent on external financing.
SINT’s materials must remain differentiated enough to earn high-value specialty-ceramics economics, not commodity contract-manufacturing economics. Gross margin determines whether commercialization can fund the platform or merely adds low-quality volume.
The operating platform has to be leveraged by commercial volume or structurally reduced; otherwise SINT’s development and manufacturing capabilities consume more cash than they can generate. Operating leverage is the difference between a scalable materials platform and a perpetual loss-making lab.
SINT needs strategic funding, non-dilutive capital, or a rapid commercial inflection before cash burn forces financing on terms that dilute existing owners’ upside. Even if the technology eventually works, the stock may not work if shareholders are diluted before adoption arrives.
A 32-person company must win through focused partnerships and a narrow set of high-probability applications, not by trying to commercialize every possible silicon nitride use case internally. Focus can conserve cash and raise the odds of a fundable win; dispersion increases the risk that no application reaches scale in time.
All standing thesis claims
Original report summary
SINT is a financing-constrained option on whether its silicon nitride ceramics can move from technical promise to repeat commercial adoption.
Bull case and bear case
Bull case and bear case for Sintx Technologies
Where the evidence on Sintx Technologies disagrees: Mixed on the latest evidence (Oct 13, 2026). Of its 5 thesis points, 2 holding and 3 weakening.
Bull case: what the evidence supports
SINT’s materials must remain differentiated enough to earn high-value specialty-ceramics economics, not commodity contract-manufacturing economics.
A 32-person company must win through focused partnerships and a narrow set of high-probability applications, not by trying to commercialize every possible silicon nitride use case internally.
Bear case: what the evidence questions
OEM qualification of SINT’s silicon nitride platform must convert niche technical interest into repeat commercial orders rather than one-off development work.
The operating platform has to be leveraged by commercial volume or structurally reduced; otherwise SINT’s development and manufacturing capabilities consume more cash than they can generate.
SINT needs strategic funding, non-dilutive capital, or a rapid commercial inflection before cash burn forces financing on terms that dilute existing owners’ upside.
Thesis-Break Engine
Thesis-break watch · Sintx Technologies
No break has crossed Sintx Technologies’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedOther material event.
Sintx Technologies filed an SEC 8-K on 2026-10-09: Other material event. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Sintx Technologies filed an SEC 8-K on 2026-10-01: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Sintx Technologies filed an SEC 8-K on 2026-08-13: Regulation FD disclosure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Medical device OEMs such as Medtronic, Stryker, or Zimmer Biomet continue standardizing on titanium, PEEK, alumina, or zirconia rather than qualifying silicon nitride.
- Incumbent ceramic suppliers match the required specifications and force SINT to compete mainly on price.
- Commercialization requires higher sales, quality-system, regulatory, or manufacturing spending before revenue scales.
- Capital markets become unavailable or punitive for small, loss-making Nasdaq medical-technology issuers.
- Loss of key technical, manufacturing, regulatory, or business-development personnel slows customer qualification.
SINT news
Loading headlines…
Financial statements
SINT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
SINT: quick answers
- What is SINT's short interest?
- As of October 30, 2026, 128,437 SINT shares were sold short, 1.70% of its shares outstanding, down 5.9% from the count before. At the stock's average daily volume that is 7.3 days to cover. FINRA publishes the count twice a month. SINT short interest history

